BioReliance Announces Presentations at "Viral Safety for Biologicals" Conference.ROCKVILLE, Md. -- BioReliance Corporation announced today that two of the company's senior scientists will be presenting at Informa Life Sciences' Viral Safety for Biologicals meeting in Cologne, Germany on June 23rd and 24th, 2009. Dr. Martin Wisher, Senior Scientific Director, and Dr. John Kolman, Senior Director of R&D, will both be discussing topics focused on the development of testing methods that help to ensure the safety of therapeutics derived from biological manufacturing processes. Dr. Kolman's presentation, titled "New Technologies for the Rapid Detection of Adventitious ADVENTITIOUS, adventitius. From advenio; what comes incidentally; us adventitia bona, goods that, fall to a man otherwise than by inheritance; or adventitia dos, a dowry or portion given by some other friend beside the parent. Viral Infections", will be presented as part of the "Latest Viral Detection Methods" track of the conference. His session will describe novel methods for detecting genetic signatures of virus infection as well as research conducted at BioReliance to understand how these technologies can be applied to the product development setting. This work will focus mainly on the performance, speed and utility of massively parallel See MPP. ("next generation") nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. sequencing for detecting virus sequences as part of a biological product development and safety strategy. Dr. Wisher's presentation, titled "Implementing an Effective Virus Risk Management Plan" will be presented as part of the "Risk Assessment: Implementation and Experiences" section of the conference. The session will be given as a case study, focusing on the development of a successful virus risk assessment and plan, per recent EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. Guidance of Viral Safety of Biotechnological IMPs, using the example of a monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing produced in Chinese Hamster Ovary ovary, ductless gland of the female in which the ova (female reproductive cells) are produced. In vertebrate animals the ovary also secretes the sex hormones estrogen and progesterone, which control the development of the sexual organs and the secondary sexual (CHO CHO Carbohydrate (chemical formla Carbon Hydrogen Oxygen) CHO Chinese Hamster Ovary CHO Chemical Hygiene Officer CHO Chief Health Officer (corporate title) ) cells. Dr. Wisher will also discuss the potential risks of viral contamination in mammalian cell manufacturing processes and the implementation of risk control strategies for raw materials, process testing and viral clearance studies. "We are very pleased that two of BioReliance's leading scientists are able to participate in this important conference," said Dr. David Onions, Chief Scientific Officer of BioReliance. "We recognize the importance of providing consistent thought leadership to the biotechnology industry with regards to product safety. We are also very pleased to present new developments in technology platforms for biosafety testing, as BioReliance is also a recognized leader in the development and advancement of new methodologies." About BioReliance BioReliance Corporation is a leading provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, cell and virus bank manufacturing, in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. and in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. toxicology, and lab animal health diagnostics. Founded in 1947 as Microbiological Associates, BioReliance is headquartered in Rockville, Maryland, has primary facilities in Rockville, Glasgow, Scotland and Stirling, Scotland, offices in Tokyo, Japan, and Bangalore, India and employs more than 650 people globally. For more information, visit www.bioreliance.com. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion